and Clinical Programs

DNA Repair

• Deffective DNA skin repair in >2 billion individuals.
• Initial focus on 1,000 xeroderma pigmentosum (XP) patients.
• Results CUV151 (n = 9), showed reduced skin damage, statistically decreased UV-erythema dose response, increased minimal erythema dose and skin pigmentation (one dose of SCENESSE^® following UV irradiation in disease free individuals).
• Initial results CUV156 (n = 6), presented to the 32nd Meeting of the Photodermatology Society as part of the 2023 American Academy of Dermatology (AAD) Meeting, showed afamelanotide reduced DNA photodamage.
• CUV152 (n = 6), ongoing.

Vitiligo

• Skin depigmentation disorder.
• Prevalence between 0.1-2% of global population.
• >250K darker skin type (IV-VI) patients in North America.
• Positive repigmentation in past studies CUV102 and CUV103.
• CUV104 (n = 6) underway with focus on SCENESSE^® as a monotherapy.
• CUV105 (n = 150) with combination NB-UVB and SCENESSE^® therapy in design.

Arterial Ischaemic Stroke (AIS)

• 15 million strokes annually, 80% ineligible for treatment.
• First study (CUV801) results (n=6) showed no safety concerns and improved neurological function.
• Second study (CUV803) commenced March 2023 (n=12).
• Initial results of CUV803 showed improvement in three patients administered PRÉNUMBRA^® Instant.
• Study extended in May 2023 from patients with mild and moderate strokes to patients with moderate-to-severe and severe strokes.

Variegate Porphyria (VP)

• Light exposure causes skin fragility.
• No existing treatment.
• 3,000-4,000 patients US/EU.
• Study CUV040 (n = 6) commenced May 2023.
• SCENESSE^® to reduce severity of phototoxicity
• and skin disease.